An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population). As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.

I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.

On November 18, MEI Pharma (SYM: MEIP) and their Japanese Big Pharma giant Kyowa Kirin announced solid results for their Lymphoma drug, zandelisib. 

Education is witnessing a massive, transformational shift. In fact, the online learning category is expected to grow more than five times over the next seven years, according to IPO Edge, which is more than two times faster that e-commerce growth between 2014 and 2019.

Wanted to give you all a quick update on Clovis (SYM: CLVS) and MEI Pharma (SYM: MEIP). The iron rule of biotech investing is to bet on the science.